Chain Drug Review - Merck’s Zocor gets additional exclusivity
Merck & Co. has received an additional six months of patent protection in the United States for its cholesterol-lowering drug Zocor. The patent, which was due to expire after December 23, 2005, now extends to June 23, 2006. Merck, which achieves annual sales of more than $6 billion with Zocor, is seeking to enhance the Zocor franchise through a partnership with Schering-Plough Corp.
Related Results
New indication approved for ZocorNew zocor labelingNew Zocor labelingGeneric Zocor to debutGeneric Zocor approved
The companies are developing a cholesterol-lowering drug called Zetia that would be used in combination with Zocor.
COPYRIGHT 2002 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
